Sato Y, Iwata S, Akita H, Sunakawa K
Department of Pediatrics, Ohta General Hospital.
Jpn J Antibiot. 1990 May;43(5):826-36.
Norfloxacin (NFLX, AM-715) is a new quinolone antibacterial agent. In the present study, we carried out laboratory and clinical investigations on NFLX in the field of pediatrics. The obtained results are summarized as follows. 1. NFLX was very active against Escherichia coli, Salmonella sp., Klebsiella sp., Enterobacter sp. and Pseudomonas aeruginosa among Gram-negative rods. Antibacterial activities of NFLX against Gram-positive cocci were lower than those against Gram-negative rods but superior to activities of usual quinolone agents. MIC values of NFLX against Campylobacter jejuni were distributed in a range of less than or equal to 0.05-0.78 micrograms/ml. 2. A peak serum level of 0.49 micrograms/ml was observed in 2 subjects and its urinary recoveries were 13.7%, 21.5%, respectively. 3. Clinical efficacies to NFLX were excellent in 25 patients and good in 9 patients with a efficacy rate of 92%. In a bacteriological examination, causative organisms were eradicated with an eradication rate of 87%. 4. No side effects were observed except eosinophilia in 1 patient. These findings indicate that NFLX will be useful and safe drug against bacterial infections in pediatrics.
诺氟沙星（NFLX，AM - 715）是一种新型喹诺酮类抗菌剂。在本研究中，我们在儿科学领域对诺氟沙星进行了实验室和临床研究。所得结果总结如下。1. 诺氟沙星对革兰氏阴性杆菌中的大肠杆菌、沙门氏菌属、克雷伯氏菌属、肠杆菌属和铜绿假单胞菌具有很强的活性。诺氟沙星对革兰氏阳性球菌的抗菌活性低于对革兰氏阴性杆菌的活性，但优于常用喹诺酮类药物。诺氟沙星对空肠弯曲菌的最低抑菌浓度（MIC）值分布在小于或等于0.05 - 0.78微克/毫升的范围内。2. 2名受试者的血清峰值水平为0.49微克/毫升，其尿回收率分别为13.7%、21.5%。3. 诺氟沙星对25例患者临床疗效极佳，9例患者疗效良好，有效率为92%。在细菌学检查中，致病微生物被根除，根除率为87%。4. 除1例患者出现嗜酸性粒细胞增多外，未观察到其他副作用。这些结果表明，诺氟沙星将是一种用于治疗儿科细菌感染的有效且安全的药物。
